Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

about

Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia.

P2860

Q37591850-7A991AFB-9CEE-4B97-8745-C9A125E9D2EF Q52631989-53F825D0-CDF6-4F58-8CE6-D0B1971E5BFD

P2860

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

Item

http://www.wikidata.org/entity/Q40213114

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Optimization of radotinib dose ...... esponse relationship analyses.

@en

type

Item

label

Optimization of radotinib dose ...... esponse relationship analyses.

@en

prefLabel

Optimization of radotinib dose ...... esponse relationship analyses.

@en

P1476

Optimization of radotinib dose ...... esponse relationship analyses.

@en

P2093

Dae Jin Cho

http://www.w3.org/2001/XMLSchema#string

Dae Young Zang

http://www.w3.org/2001/XMLSchema#string

Dong-Wook Kim

http://www.w3.org/2001/XMLSchema#string

Hayeon Noh

http://www.w3.org/2001/XMLSchema#string

Hye Lin Park

http://www.w3.org/2001/XMLSchema#string

Jangik I Lee

http://www.w3.org/2001/XMLSchema#string

Min Soo Park

http://www.w3.org/2001/XMLSchema#string

Suk Joong Oh

http://www.w3.org/2001/XMLSchema#string

Sung-Hyun Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical trial designs for cytostatic agents: are new approaches needed?

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.

Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.

Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors.

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

P304

1856-1864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2015.1113278

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26666371

http://www.w3.org/2001/XMLSchema#string

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

about

P2860

P2860

Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698